More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.30B
EPS
-1.06
P/E ratio
--
Price to sales
2.43
Dividend yield
--
Beta
1.093443
Previous close
$11.30
Today's open
$11.31
Day's range
$11.05 - $11.51
52 week range
$9.82 - $21.45
show more
CEO
Frank Leonard
Employees
1605
Headquarters
St. Helier, JE
Exchange
Nasdaq Global Select
Shares outstanding
116915959
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line tre.
Business Wire • Nov 13, 2026

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.
The Motley Fool • Nov 10, 2026

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune.
Business Wire • Nov 9, 2026

Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Zacks Investment Research • Nov 2, 2026

NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.
The Motley Fool • Nov 2, 2026

NovoCure Q3 Earnings Call Highlights
NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.
MarketBeat • Oct 29, 2026

NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackmann - Chief Financial Officer Uri Weinberg - Chief Innovation Officer & Chief Medical Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Tanmay Patwardhan - JPMorgan Chase & Co. Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions] Please note, this call may be recorded.
Seeking Alpha • Oct 29, 2026

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Novocure's strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launchin.
Business Wire • Oct 29, 2026

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.
Zacks Investment Research • Oct 29, 2026

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.
Business Wire • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell NovoCure Limited commission-free¹. Build wealth for the long term using automated trading and transfers.